becton dickinson compani
tough week bd
lower fy ep
due pump ship hold announc yesterday assum reduct
pump sale fy assum come back
lost competitor includ also assum lost
dispos sale dispos revenue per pump per year ep
assum ep growth lower base add back profit
delay pump capit sale subtract dispos associ
lost pump convers yesterday suggest
specif issu see new opportun
novemb mention delay pump shipment due softwar upgrad
januari said resum ship pump yesterday announc ship
hold us alari pump cut guidanc softwar upgrad appar
trigger fda food drug administr review chang made
alari pump last year fda inform requir
submit singl comprehens file convers industri player suggest
may adequ adjust devic compli fda guidelin
alert alarm importantli fda recal patient safeti issu
lower po
tough week paclitaxel knee data show limit efficaci
year price cut china wors expect alari pump ship hold
surpris lower po lower earn
assum multipl lower ep arriv one year po versu prior
po ep issu pump space new bdx interconnect
pharmaci make pump system attract expect major bdx
custom wait fix issu within year would expect issu
entir behind without linger effect reiter buy rate
full definit iqmethod sm measur see page
bofa secur seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
becton dickinson compani
becton dickinson co bd diversifi global
medic technolog compani produc
medic devic instrument system reagent
healthcar life scienc research clinic
diagnost pharmaceut market bd
grown larg medic conglomer
significantli expand compani medic
technolog footprint infus medic
well regard provid medic
suppli diagnost life scienc tool
seri growth profit initi
result better organ sale ep growth
led multipl expans acquisit
carefus bard provid
unmatch portfolio new growth
plu organ revenu growth
becton dickinson compani februari
becton dickinson compani februari
becton dickinson compani
price object base ep estim multipl
line larg cap peer think warrant given long term growth
profil mid-singl digit
downsid risk po increas competit slower growth emerg
market price eros lower healthcar util trend soft uptak new
diagnost product slower growth hospit capit spend
bob hopkin herebi certifi view express research report accur
reflect person view subject secur issuer also certifi
part compens directli indirectli relat specif
recommend view express research report
becton dickinson compani
becton dickinson compani februari
qualiti earn
iqmethod smi set bofa global research standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa global research
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
becton dickinson compani februari
